Research programme: skin disorders therapeutics - AnGes MG
Latest Information Update: 21 May 2010
At a glance
- Originator AnGes MG
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 21 May 2010 No development reported - Preclinical for Skin disorders in Japan (unspecified route)